

# Yuichi Sugiyama

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6440467/publications.pdf>

Version: 2024-02-01

18  
papers

1,149  
citations

687363

13  
h-index

839539

18  
g-index

18  
all docs

18  
docs citations

18  
times ranked

1131  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption. <i>Biopharmaceutics and Drug Disposition</i> , 2013, 34, 45-78.	1.9	345
2	Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug-Drug Interaction Evaluation: Perspectives From the International Transporter Consortium. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 836-864.	4.7	141
3	Investigation of the Impact of Substrate Selection on In Vitro Organic Anion Transporting Polypeptide 1B1 Inhibition Profiles for the Prediction of Drug-Drug Interactions <sup>&lt;sup&gt;/&gt;</sup> . <i>Drug Metabolism and Disposition</i> , 2015, 43, 235-247.	3.3	125
4	Quantitative Analyses of Hepatic OATP-Mediated Interactions Between Statins and Inhibitors Using PBPK Modeling With a Parameter Optimization Method. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 100, 513-523.	4.7	81
5	Inhibitory effects of p-aminohippurate and probenecid on the renal clearance of adefovir and benzylpenicillin as probe drugs for organic anion transporter (OAT) 1 and OAT3 in humans. <i>European Journal of Pharmaceutical Sciences</i> , 2014, 59, 94-103.	4.0	78
6	Ethnic Variability in the Plasma Exposures of OATP1B1 Substrates Such as HMG-CoA Reductase Inhibitors: A Kinetic Consideration of Its Mechanism. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 94, 37-51.	4.7	76
7	PBPK Modeling of Coproporphyrin I as an Endogenous Biomarker for Drug Interactions Involving Inhibition of Hepatic OATP1B1 and OATP1B3. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2018, 7, 739-747.	2.5	51
8	Clarification of the Mechanism of Clopidogrel-Mediated Drug-Drug Interaction in a Clinical Cassette Small-dose Study and Its Prediction Based on In Vitro Information. <i>Drug Metabolism and Disposition</i> , 2016, 44, 1622-1632.	3.3	41
9	Comparison of Methods for Estimating Unbound Intracellular-to-Medium Concentration Ratios in Rat and Human Hepatocytes Using Statins. <i>Drug Metabolism and Disposition</i> , 2017, 45, 779-789.	3.3	41
10	Intestinal P-gp and Putative Hepatic OATP1B Induction: International Transporter Consortium Perspective on Drug Development Implications. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 55-64.	4.7	38
11	A Clinical Cassette Dosing Study for Evaluating the Contribution of Hepatic OATPs and CYP3A to Drug-Drug Interactions. <i>Pharmaceutical Research</i> , 2017, 34, 1570-1583.	3.5	34
12	Mechanisms of Pharmacokinetic Enhancement Between Ritonavir and Saquinavir; Micro/Small Dosing Tests Using Midazolam (CYP3A4), Fexofenadine (P-glycoprotein), and Pravastatin (OATP1B1) as Probe Drugs. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 654-661.	2.0	30
13	Virtual Clinical Studies to Examine the Probability Distribution of the AUC at Target Tissues Using Physiologically-Based Pharmacokinetic Modeling: Application to Analyses of the Effect of Genetic Polymorphism of Enzymes and Transporters on Irinotecan Induced Side Effects. <i>Pharmaceutical Research</i> , 2017, 34, 1584-1600.	3.5	18
14	Clinical Relevance of Hepatic and Renal P-gp/BCRP Inhibition of Drugs: An International Transporter Consortium Perspective. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 573-592.	4.7	15
15	Development of a Support Vector Machine-Based System to Predict Whether a Compound Is a Substrate of a Given Drug Transporter Using Its Chemical Structure. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 2222-2230.	3.3	13
16	Is Ethnic Variability in the Exposure to Rosuvastatin Explained Only by Genetic Polymorphisms in OATP1B1 and BCRP or Should the Contribution of Intrinsic Ethnic Differences in OATP1B1 Be Considered?. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 2227-2230.	3.3	10
17	In Silico Prediction of Major Clearance Pathways of Drugs among 9 Routes with Two-Step Support Vector Machines. <i>Pharmaceutical Research</i> , 2018, 35, 197.	3.5	10
18	Direct and Rapid Genotyping of SLCO1B1 388A>G and 521T>C in Human Blood Specimens Using the SmartAmp-2 Method. <i>AAPS Journal</i> , 2013, 15, 618-622.	4.4	2